Effect of interleukin-6 neutralization on CYP3A11 and metallothionein-1/2 expressions in arthritic mouse liver
Introduction
Cytochrome P450 superfamily monooxygenases are important for the metabolism of variety of an endogenous and exogenous compounds. The regulation of cytochrome P450 genes and the variation of cytochrome P450 activities can be affected by a number of factors, such as xenobiotics and diseases. Suppression of the drug-metabolizing capability results in various adverse effects and/or elevation of blood drug concentrations. It has been known that during infections or inflammation, the hepatic drug-metabolizing capability is reduced in experimental animals and humans (Iber et al., 1999, Morgan, 1997). This phenomenon suggests that infections and inflammation down-regulate cytochrome P450 such as CYP3A, cytochrome P450 gene expressions and their protein enzymatic activities (Li-Masters and Morgan, 2002, Sewer et al., 1998). Evidence has revealed that inflammatory cytokines, such as interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF) α, play important roles in cytochrome P450 mRNA regulation (Morgan, 1997). Down-regulation of cytochrome P450 families results in changes of pharmacokinetics, metabolism, distribution and excretion of endogenous substances, exogenous drugs and chemicals. Many down-regulation studies concerned with cytochrome P450 families have focused on the acute phase response to proinflammatory substances such as lipopolysaccharide (LPS), turpentine, or Bacillus Calmette-Guerin administration (Ashino et al., 2004, Siewert et al., 2000). On the other hand, the changes in cytochrome P450 families under chronic inflammatory conditions have not yet been elucidated.
Rheumatoid arthritis is one of the most common autoimmune diseases (Firestein and Zvaifler, 1992). It is clearly shown that IL-1 and TNFα play important roles in the development of rheumatoid arthritis (Dayer, 2002, Taylor, 2003). Furthermore, rheumatoid arthritis pathogenesis itself enhances production of not only IL-1 and TNFα but also other cytokines such as IL-6 (Feldmann et al., 1996, Horai et al., 2000). Human T-cell leukemia virus type I (HTLV-I) is known as the causative insult of adult T-cell leukemia (Sugamura and Hinuma, 1993, Yoshida, 1993). Nishioka et al. (1989) firstly reported a patient with chronic inflammatory arthropathy infected with HTLV-I. Subsequently, Iwakura et al. (1991) found that HTLV-I could induce arthritis in mice. The HTLV-I transgenic mice produced by Iwakura et al. (1991) have been shown to develop chronic inflammatory polyarthropathy with a high incidence. The histopathology of HTLV-I transgenic mice is very similar to that of rheumatoid arthritis in humans, showing marked synovial and periarticular inflammation with articular erosion caused by invasion of granulation tissues (Yamamoto et al., 1993). It seems that the HTLV-I transgenic mouse is likely to be the best animal model for rheumatoid arthritis.
Metallothionein-1/2 (metallothionein) is a small, cysteine-rich, metal-binding protein. Metallothionein is capable of not only reducing metal toxicity but also scavenging free radicals or regulating metal-metabolism. Metallothionein synthesis is induced by various stimuli such as heavy metals, oxidative stress, cytokines and inflammatory diseases (Oguro and Yoshida, 2004). Metallothionein induction by LPS has been shown to be regulated through IL-6 proofed by IL-6 gene deficient mice. A signal transducer and activator of transcription (STAT) 1/STAT3 binding site exists in the promoter region of the metallothionein gene suggesting that STAT1/3 mediated signal pathway is a dominant signal transduction for LPS-mediated metallothionein induction (Lee et al., 1999).
Rheumatoid arthritis is characterized by not only chronic inflammation of the multiple joints but also systemic inflammatory responses. In particular, the liver expresses various enzymes such as drug metabolizing enzymes and is subject to affect inflammatory diseases and/or oxidative stress. Furthermore, studies on cytochrome P450 and metallothionein gene expressions in the livers by IL-6 neutralization are scarce and remain to be explored though IL-6 neutralizing antibody is used to treat rheumatoid arthritis. Considering the aforementioned findings, we investigated the relationship between changes in cytochrome P450 and metallothionein expressions and IL-6 neutralization in chronic inflammation disease model mice, HTLV-I transgenic mice.
Section snippets
Reagents
Deoxycytidine 5′-[α-32P]-triphosphate (3000 Ci/mmol) and adenosine 5′-[γ-32P]-triphosphate (5000 Ci/mmol) were obtained from Japan Isotope Association (Tokyo, Japan). Complete protease inhibitor cocktail was obtained from Roche Diagnostics (Mannheim, Germany). Anti-rat polyclonal CYP3A2 antibodies were obtained from Daiichi Pure Chemicals Co., Ltd. (Tokyo, Japan). Monoclonal antibody against STAT1 (C terminus) and STAT3 was obtained from BD Biosciences Transduction Laboratories (Lexington, KY).
Arthritic mouse and change of serum inflammatory cytokine concentrations by development of rheumatoid arthritis
Fig. 1-A shows the features of non-arthritic mouse and arthritic mouse, respectively. The posterior limb joints of the arthritic mouse were swollen as compared with those of the non-arthritic mouse. Moreover, some mice used in this study showed swelling of anterior limb joints in addition to posterior joints. HTLV-I transgenic mice start to develop arthritis spontaneously at 4 weeks of age, and 60% and 80% of the mice are affected at 3 months and 6 months of age, respectively. The ages of
Discussion
Mechanistic studies on the development of rheumatoid arthritis have been carried out by many researchers. Recently, human-type anti-inflammatory cytokine antibodies, IL-1β, IL-6, TNFα and their receptors, have been employed and developed for rheumatoid arthritis therapy resulting in effective treatment for rheumatoid arthritis. However, the effects of cytokine targeted therapies on other organs remain to be explored. In this study, we focused on the effect of IL-6 neutralization and
Acknowledgments
We thank J. Sugiuchi and H. Tomiyama for their technical assistance. We also thank Dr. A. Naganuma (Laboratory of Molecular and Biochemical Toxicology, Tohoku University, Sendai, Japan) and Dr. K. Nose (Department of Microbiology, Showa University) for kindly providing cDNA probes of mouse metallothionein-1 and rat GAPDH, respectively. A part of this study was supported by a Grant-in-Aid from the Ministry of Education, Science and Culture, Japan.
References (34)
- et al.
Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response
Biochem. Biophys. Res. Commun.
(2002) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
Anal. Biochem.
(1976)- et al.
Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction
Anal. Biochem.
(1987) - et al.
Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure
J. Card. Fail.
(2002) - et al.
Down-regulation of phenobarbital-induced cytochrome P4502B mRNAs and proteins by endotoxin in mice: independence from nitric oxide production by inducible nitric oxide synthase
Biochem. Pharmacol.
(2002) - et al.
Protein measurement with the Folin phenol reagent
J. Biol. Chem.
(1951) - et al.
Chronic inflammatory arthropathy associated with HTLV-I
Lancet
(1989) - et al.
The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature
J. Biol. Chem.
(1964) - et al.
Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent
Hepatology
(2000) Assay of hepatic microsomal testosterone hydroxylases by high-performance liquid chromatography
Anal. Biochem.
(1984)
P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR
Arch. Biochem. Biophys.
Evidence for singlet oxygen involvement in rat and human cytochrome P450-dependent substrate oxidations
Drug Metab. Pharmacokinet.
HTLV-1 Tax: regulation of gene expression and disease
Trends Microbiol.
Involvement of interleukin-6 and tumor necrosis factor alpha in CYP3A11 and 2C29 down-regulation bacillus Calmette-Guerin and lipopolysaccharide in mouse liver
Drug Metab. Dispos.
Metallothionein: the multipurpose protein
Cell. Mol. Life Sci.
Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis?
J. Rheumatol., Suppl.
Role of cytokines in rheumatoid arthritis
Annu. Rev. Immunol.
Cited by (29)
Downregulation of the gene expression of Cyp2c29 and Cyp3a11 by cecal ligation and puncture-induced sepsis is associated with interleukin-6
2023, International ImmunopharmacologyDrug-metabolizing enzymes and inflammatory responses
2022, Biochemistry of Drug Metabolizing Enzymes: Trends and ChallengesInflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment
2020, Pharmacology and TherapeuticsCitation Excerpt :Similar downregulation of DMETs in preclinical models of certain chronic inflammatory diseases has been recently reviewed (Wu & Lin, 2019). Various models of colitis (Chaluvadi, Kinloch, et al., 2009; Masubuchi et al., 2008) and arthritis (Ashino et al., 2007; Dickmann et al., 2012; Sanada et al., 2011) show diminished hepatic expression and/or activity of many CYP450 enzymes (CYP3A, 4A, 2C, 1A2, and 2E1). Such down-regulation appears to correlate with an increase in pro-inflammatory cytokine concentrations (IL-6 and TNF-α, as well as IFN-γ, IL-2, IL-1α, and IL-1β) (Chaluvadi, Kinloch, et al., 2009; Masubuchi et al., 2008; Sanada et al., 2011) and could explain the increased concentrations of propranolol (Guirguis & Jamali, 2003) and verapamil (Ling & Jamali, 2005) observed in adjuvant-induced arthritis.
The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders
2019, Journal of Food and Drug AnalysisCitation Excerpt :The expression changes in Cyp2b and Cyp3a enzymes are strongly correlated with the increased levels of TNF-α, IL-1β, and IL-6 in the liver [74]. Inhibition of cytokines production by non-steroidal anti-inflammatory drugs (NSAIDs) or treatment with antibodies against specific cytokines can reverse the reduction of CYP enzymes and the changes in the clearance of propranolol in RA animal models [76,77], confirming that cytokines have an important role in the regulation of CYP enzymes in RA. In humans, it was recently reported that the levels of inflammatory cytokines are negatively associated with CYP3A4 phenotype in RA patients [78].
Regulation of Drug-Metabolizing Enzymes and Drug Metabolism by Inflammatory Responses
2017, Drug Metabolism in Diseases